The University of Rouen Normandie, together with its partners in the Normandy ecosystem, is committed to working alongside its teaching and research staff to support them in their approach to business creation, providing them with the keys to understanding how to get their projects off the ground. Focus on the university’s success stories.
ALGA BIOLOGICS
Alga biologics is a young innovative start-up founded in November 2021 by Muriel BARDOR on the basis of research work carried out in the GLYCOMEV laboratory of the University of Rouen Normandy and the Carnot Chemistry Innovation (I2C).
Researchers at the GLYCOMEV laboratory have successfully used microalgae to produce functional antibodies directed against viruses or cancers.
Alga biologics aims to use microalgae on an industrial scale as a biorefinery for the sustainable production of therapeutic antibodies.
CHEMFORASE
Chemforase®is a young, innovative start-up founded in 2016 by Émilie DAVID on the basis of research work carried out in the COBRA laboratory at the University of Rouen Normandie. This research focused on the purification of an enzyme used as an antidote to neurotoxic products.
Research carried out in the laboratory led to the filing of a patent in 2011 on an affinity resin, Hupresin®, enabling the production and purification of cholinesterase and butyrylcholinesterase, marketed by the Company. The company develops and markets other specific affinity resins, notably for the purification of enzymes for medical use.
Chemforase® has been housed in the COBRA laboratory since January 2016.
GENEXPATH
Genexpath®is a young innovative start-up founded in November 2020 by Juliette RENAULD on the basis of research work carried out in the UMR1245-GPMCND laboratory of the University of Rouen Normandy and INSERM in collaboration with the Henri Becquerel Center.
This research has led to a series of inventions and know-how which have been the subject of several patent applications, and the creation of various software programs which have been the subject of maturation financed by Normandie Valorisation. Having been granted an exclusive license for these innovative technologies by the Université de Rouen Normandie on behalf of Inserm and the Centre Henri Becquerel, Genexpath now develops and produces reliable, rapid cancer diagnostic kits that do not require the purchase of additional equipment.
TARGEDYS
TargEDys®was founded in 2011 on the basis of research carried out by Professor Sergueï FETISSOV and Professor Pierre DECHELOTTE, Head of the Nutrition Department and the Centre Spécialisé dans l’Obésité (CSO) at Rouen University Hospital.
These researchers, co-founders of the company, were the first to discover the molecular link between the gut-brain axis. Their research led to the filing of a series of patents, which are now exploited exclusively by the company under a licensing agreement signed in 2016 with Inserm Transfert, on behalf of Inserm, the University of Rouen Normandy and Rouen University Hospital.
Its team of researchers is housed within laboratories U1073-ADEN and U1239-DC2N, INSERM joint research units at the Université de Rouen Normandie.